Table 1.
Leading Cancer Sites for American Indians/Alaska Nativesa compared to Non-Hispanic Whites for the United States, Males, All ages, PRCDA Counties, US, 2010–2015
| Overall | Northern Plains | Alaska | Southern Plains | Pacific Coast | East | Southwest | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer Site | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb,AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN (W) Ratec | RRd |
| Prostate | 1(1) | 86.7 (105.4) | 0.82e | 2(1) | 110.7(106.8) | 1.04 | 3(1) | 58.2(90.0) | 0.65e | 1(1) | 116.8 (99.2) | 1.18e | 1(1) | 81.3(105.8) | 0.77e | 1(1) | 71.4 (113.5) | 0.63e | 1(1) | 64.3(89.7) | 0.72e |
| Lung and Bronchus | 2(2) | 76.4 (68.2) | 1.12e | 1(2) | 122.4(68.9) | 1.77e | 1(2) | 118.4(60.1) | 1.97e | 2(2) | 115.9 (83.7) | 1.38e | 2(2) | 72.6(62.0) | 1.17e | 2(2) | 49.8 (76.4) | 0.65e | 4(2) | 24.3(56.9) | 0.43e |
| Colon and Rectum | 3(3) | 57.5(42.3) | 1.36e | 3(3) | 71.7(43.0) | 1.67e | 2(3) | 95.6(39.2) | 2.44e | 3(3) | 71.9(46.3) | 1.56e | 3(3) | 48.5(41.2) | 1.18e | 3(4) | 39.9(44.1) | 0.90 | 2(3) | 42.4(38.7) | 1.10 |
| Kidney and Renal Pelvis | 4(7) | 35.7 (21.5) | 1.66e | 4(7) | 46.4(21.7) | 2.14e | 5(5) | 27.2(21.3) | 1.28 | 4(6) | 43.2(23) | 1.87e | 5(7) | 27.4(20.9) | 1.31e | 5(7) | 18.8(23.1) | 0.81 | 3(7) | 37.2(18.7) | 1.99e |
| Liver and Intrahepatic Bile Duct | 5(11) | 22.9(10.0) | 2.30e | 6(15) | 24.3(7.7) | 3.17e | 9(11) | 17.3(10.4) | 1.67e | 8(11) | 22.0(9.9) | 2.24e | 4(11) | 27.9(11.1) | 2.53e | 4(11) | 18.8(10.8) | 1.74e | 5(11) | 21.3(8.3) | 2.58e |
| Urinary Bladder | 6(4) | 21.3(39.8) | 0.53e | 5(4) | 24.9(38.2) | 0.65e | 7(4) | 25.6(38.3) | 0.67e | 5(4) | 32.7(35.7) | 0.92 | 6(5) | 26.0(39.0) | 0.67e | 7(3) | 15.0(44.1) | 0.34e | 12(4) | 8.2(35.3) | 0.23e |
| Non-Hodgkin Lymphoma | 7(6) | 18.7(23.3) | 0.80e | 7(6) | 20.8(24.1) | 0.86 | 8(6) | 20.1(20.6) | 0.98 | 6(7) | 28.0(22.0) | 1.27e | 7(6) | 20.7(23.7) | 0.87 | 10(6) | 9.4(24.6) | 0.38e | 8(6) | 11.7(19.4) | 0.60e |
| Oral Cavity and Pharynx | 8(9) | 17.7(18.4) | 0.96 | 8(9) | 20.0(17.1) | 1.17 | 6(8) | 25.7(15.2) | 1.69e | 7(8) | 23.7(20.4) | 1.16 | 8(8) | 19.5(19.1) | 1.02 | 6(9) | 15.8(19.3) | 0.82 | 11(9) | 9.1(16.0) | 0.57e |
| Leukemia | 9(8) | 14.4(18.5) | 0.78e | 9(8) | 16.8(18.9) | 0.89 | 11(9) | 14.6(14.4) | 1.02 | 10(9) | 18.5(17.3) | 1.07 | 9(9) | 15.1(18.2) | 0.83 | 8(8) | 12.9(20.0) | 0.64e | 9(8) | 9.8(16.1) | 0.61e |
| Pancreas | 10(10) | 14.1(14.1) | 1.00 | 11(10) | 14.1(13.9) | 1.01 | 10(10) | 15.3(13.1) | 1.16 | 11(10) | 16.1(13.0) | 1.24e | 10(10) | 15.0(14.0) | 1.07 | 9(10) | 10.0(15.3) | 0.65e | 7(10) | 12.6(12.9) | 0.98 |
| Stomach | 11(15) | 13.9(7.6) | 1.83e | 10(14) | 15.4 (7.8) | 1.97e | 4(14) | 28.2(7.2) | 3.93e | 12(14) | 11.4(6.9) | 1.64e | 13(14) | 8.5 (7.5) | 1.13 | 11(15) | 9.4(8.6) | 1.10 | 6(16) | 17.0(6.0) | 2.84e |
| Melanoma of the Skin | 12(5) | 10.0(34.1) | 0.29e | 15(5) | 8.7(27.1) | 0.32e | 18(7) | 3.8(18.7) | 0.20e | 9(5) | 19.8(27) | 0.73e | 11(4) | 10.4(39.5) | 0.26e | 12(5) | 6.4(35.1) | 0.18e | 15(5) | 5.3(31.8) | 0.17e |
| Myeloma | 13(16) | 8.6(7.2) | 1.20e | 14(13) | 10.4(7.8) | 1.34 | 17(16) | 6.6(5.6) | 1.18 | 13(15) | 9.9(6.6) | 1.50e | 16(16) | 6.5(7.2) | 0.91 | 15(16) | 4.5(7.8) | 0.57 | 10(17) | 9.8(5.8) | 1.68e |
| Esophagus | 14(13) | 8.1(8.4) | 0.96 | 13(11) | 10.9(8.9) | 1.23 | 12(12) | 12.2(9) | 1.36 | 14(13) | 9.4(7.7) | 1.23 | 14(13) | 7.7 (8.4) | 0.92 | 14(14) | 5.4(8.7) | 0.63 | 14(14) | 5.8(7.9) | 0.73e |
| Testis | 15(17) | 6.9(7.0) | 0.98 | 16(16) | 7.4(7.3) | 1.01 | 13(15) | 8.5(6.8) | 1.25 | 18(18) | 5.8(5.6) | 1.04 | 12(15) | 8.5 (7.4) | 1.15 | 13(17) | 5.6(7.2) | 0.78 | 13(15) | 6.4(6.2) | 1.03 |
Source: Cancer registries in the Centers for Disease Control and Prevention’s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER)
PRCDA indicates Purchased/Referred Care Delivery Areas; AI/AN: American Indians/Alaska Natives; W: non-Hispanic white.
AI/AN race is reported by NPCR and SEER registries or through linkage with the IHS patient registration database. Includes only AI/AN of non-Hispanic origin.
Rank based on rates. AI/AN (white)
Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups - Census P25–1130).
Rate ratios (RR) are AI/AN versus White and are calculated in SEER*Stat prior to rounding of rates and may not equal RR calculated from rates presented in table.
Indicates RR is statistically significant (p<0.05).
Years of data and registries used: 1999–2015 (48 states): AK*, AL*, AZ*, CA*, CO*, CT*, DE, DC, FL*, GA, HI, IA*, ID*, IL, IN*, KS*, KY, LA*, MA*, MD, ME*, MI*, MN*, MO, MT*, ND* NE*, NH, NJ, NM*, NV*, NY*, NC*, OH, OK*, OR*, PA*, RI*, SC*, TX*, TN, UT*, VT, VA, WA*, WI*, WV, WY*; 2000–2015: AR, SD*; 2003–2015: MS*. *States with at least one county designated as PRCDA.
Percent regional coverage of AI/AN in PRCDA counties to AI/AN in all counties: Northern Plains=54.2%; Alaska=100%; Southern Plains=56.5%; Southwest=83.8%; Pacific Coast=60.2%; East=16.4%; Total US=53.0%.